Price History

Hover for the daily close. The dotted line marks the period open.

Compare DCOY with… →

DCOY Key Statistics

As of Sep 4, 2026

Trading

Open: $2.91
Previous Close: $2.88
Day's Range: 2.69–2.91
52-Week Range: 2.69–70.80
Volume: 26.90K
Beta: 0.56

Valuation

Market Cap: $1.76M
P/E Ratio: 0.02
P/S ratio: 7.74
EPS (ttm): 108.33

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$12.52M
Profit margin: 0.00%
Shares Outstanding: 655.18K
1-Year Return: −95.27%

Dividend and dates

Avg Volume: 253.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DCOY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−33.90%−97.65%−65.46%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−65.46%
2025	−97.65%
2024	−64.62%
2023	−57.52%
2022	−87.66%
2021	−45.49%
2020	−75.93%
2019	−54.18%
2018	−90.54%
2017	−33.90%
2016 (partial year)	−53.11%

As of September 4, 2026.

DCOY Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$12.52M	—
2024	$0.00	−$5.58M	—
2023	$0.00	−$12.54M	—
2022	$0.00	−$31.61M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$12.61M	−$12.52M	—
2024	$0.00	—	−$5.73M	−$5.58M	—
2023	$0.00	—	−$12.89M	−$12.54M	—
2022	$0.00	—	−$22.98M	−$31.61M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DCOY Valuation vs Biotechnology Median

Median of 656 stocks

Metric	DCOY	Biotechnology median	vs median
P/E	0.02	12.57	0.0x the median
P/S ratio	7.74	15.26	49% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Decoy Therapeutics Inc. (DCOY) carries a market capitalisation of $1.76M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 11.

The 52-week range on file runs from $2.69 to $70.80. DCOY last closed at $2.69 on September 4, 2026. That is −$0.19 (−6.60%) against the previous close.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $12.52M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 108.33.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 0.02 times earnings. That is 0 times the Biotechnology median of 12.57. The price-to-sales ratio is 7.74. On price-to-sales that is 49.27% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.56. Daily returns over the trailing 10 years annualize to a volatility of 132.69%. The trailing one-year price return is −95.27%. Measured over 10 years, that is −77.98% a year compounded.

Growth & Income

No dividend is on file for DCOY.

2026 is still running; the price is −65.46% year to date. The strongest complete calendar year on file is 2017 at −33.90%; the weakest is 2025 at −97.65%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Decoy Therapeutics Inc. (DCOY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Decoy Therapeutics Inc.	DCOY	$1.76M	0.0
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Decoy Therapeutics Inc. trades at a P/E of 0.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Decoy Therapeutics Inc.

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.

Visit website →

Decoy Therapeutics Inc. (DCOY) Stock Analysis